Ganitumab disappoints in pancreatic cancer: Amgen halts Phase III Study
In a press release on August 8, 2012, Amgen announced that the company was halting a late-stage trial of its monoclonal antibody IGF-1 receptor antagonist ganitumab (AMG-479).
In a press release on August 8, 2012, Amgen announced that the company was halting a late-stage trial of its monoclonal antibody IGF-1 receptor antagonist ganitumab (AMG-479).
In news that is bound to excite breast cancer patients and investors, Genentech/Roche/Immunogen issued press releases on August 26, 2012, confirming that their drug-of-the-moment T-DM1 (trastuzumab emtansine) offers… read more.
by Zara Qadir – On the occasion of its 40th Anniversary, the European Association of Hospital Pharmacists (EAHP) recorded the highest number of attendees at its annual Congress… read more.
by Zara Qadir – The role of consultant pharmacist was introduced seven years ago by the National Health Service (NHS) in the UK, with the intention of improving… read more.
by Christine Clark – Changes in the diagnosis and treatment of cancer form the basis for future developments. There have been many revolutions in medical science over the… read more.
by Zara Qadir – Five years of evolution in Hospital Pharmacy. The 40th EAHP meeting provided an opportunity for Tajda Miharija-Gala and Juraj Sykora, Directors of Professional Development,… read more.
by Zara Qadir reporting on the presentation by Yechiel Hekster (pictured), Professor of Clinical Pharmacy, and a member of The Netherlands Medicines Evaluation Board.
by Bruce Sylvester taken from the New England Journal of Medicine (NEJM) Vismodegib (Erivedge), a new skin cancer drug for advanced basal cell carcinoma, was called “the greatest… read more.
by Bruce Sylvester – In a randomized Phase II study presented at ASCO, investigators reported that 6 months of treatment with the targeted drug abiraterone (Zytiga) when added… read more.
by Bruce Sylvester – Investigators from a Phase III trial reported at ASCO that chemotherapy-induced nausea and vomiting (CINV) which is unresponsive to conventional treatments reponds to olanzapine… read more.
by Bruce Sylvester – Results from an expanded Phase IB trial presented at ASCO suggest that combination therapy with two investigational and targeted drugs, BRAF inhibitor dabrafenib and… read more.
by Bruce Sylvester – Investigators reported at ASCO that relapsed follicular lymphoma patinets treated with combination lenalidomide (Revlimid) and rituximab (Rituxan) achieved a higher percentage of overall response… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.